Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.

Also called NCT02296190

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 199 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02296190
Other papers using this trial's data
  • Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm Journal of the American College of Cardiology, 2018-07-31 DOI, PubMed 30049309

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02296190. Randomized; double masking; primary purpose treatment. Start 2015-03-27 (registry gives no type); primary completion 2016-12 (actual). Results posted on 2020-12-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
Acronym
NODE-1
Condition
Paroxysmal Supraventricular Tachycardia (PSVT)
Intervention (Drug)
Etripamil
Intervention (Drug)
Placebo
Lead sponsor
Milestone Pharmaceuticals Inc. (class: other)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02296190
Content hash
34a01edbabaf77d405d820a3226171679993dc6168d2358556ebcab234ac2264